10x Genomics Inc (NASDAQ: TXG) kicked off on Tuesday, down -3.60% from the previous trading day, before settling in for the closing price of $9.45. Over the past 52 weeks, TXG has traded in a range of $6.78-$24.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 19.96% over the past five years. While this was happening, its average annual earnings per share was recorded 19.65%. With a float of $103.46 million, this company’s outstanding shares have now reached $109.08 million.
Let’s look at the performance matrix of the company that is accounted for 1306 employees. In terms of profitability, gross margin is 68.79%, operating margin of -27.6%, and the pretax margin is -24.56%.
10x Genomics Inc (TXG) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Health Information Services Industry. The insider ownership of 10x Genomics Inc is 17.13%, while institutional ownership is 90.02%. The most recent insider transaction that took place on May 22 ’25, was worth 77,540. In this transaction Chief Executive Officer of this company sold 9,343 shares at a rate of $8.30, taking the stock ownership to the 1,083,625 shares. Before that another transaction happened on May 22 ’25, when Company’s insider sold 7,485 for $8.30, making the entire transaction worth $62,120. This insider now owns 448,374 shares in total.
10x Genomics Inc (TXG) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 19.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.59% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Take a look at 10x Genomics Inc’s (TXG) current performance indicators. Last quarter, stock had a quick ratio of 4.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.82. Likewise, its price to free cash flow for the trailing twelve months is 25.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.30, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.96 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
10x Genomics Inc (NASDAQ: TXG) saw its 5-day average volume 4.33 million, a positive change from its year-to-date volume of 3.26 million. As of the previous 9 days, the stock’s Stochastic %D was 78.98%. Additionally, its Average True Range was 0.58.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 22.25%, which indicates a significant decrease from 60.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.50% in the past 14 days, which was lower than the 76.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.60, while its 200-day Moving Average is $14.29. Nevertheless, the first resistance level for the watch stands at $9.40 in the near term. At $9.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.92. If the price goes on to break the first support level at $8.89, it is likely to go to the next support level at $8.67. The third support level lies at $8.37 if the price breaches the second support level.
10x Genomics Inc (NASDAQ: TXG) Key Stats
The company with the Market Capitalisation of 1.14 billion has total of 123,134K Shares Outstanding. Its annual sales at the moment are 610,790 K in contrast with the sum of -182,630 K annual income. Company’s last quarter sales were recorded 154,880 K and last quarter income was -34,360 K.
